Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan.
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan.
Eur J Pharm Sci. 2018 Mar 1;114:13-23. doi: 10.1016/j.ejps.2017.11.014. Epub 2017 Nov 22.
Among the resistant isolates of tuberculosis (TB), the multidrug resistance tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) are the areas of growing concern for which the front-line antibiotics are no more effective. As a result, the search of new therapeutic targets against TB is an imperative need of time. On the other hand, the target identification is an a priori step in drug discovery based research. Furthermore, the availability of the complete proteomic data of extensively drug resistant Mycobacterium tuberculosis (XDR-MTB) made it possible to carry out in silico analysis for the discovery of new drug targets. In the current study, we aimed to prioritize the potential drug targets among the hypothetical proteins of XDR-TB via subtractive genomics approach. In the subtractive genomics, we stepwise reduced the complete proteome of XDR-MTB to only two hypothetical proteins and evidently proposed them as new therapeutic targets. The 3D structure of one of the two target proteins was predicted via homology modeling and later on, validated by various analysis tools. Our study suggested that the domains identified and the motif hits found in the sequences of the shortlisted drug targets are crucial for the survival of the XDR-MTB. To the best of our knowledge, the current study is the first attempt in which the complete proteomic data of XDR-MTB was subjected to the computational subtractive genomics approach and therefore, would provide an opportunity to identify the unique therapeutic targets against deadly XDR-MTB.
在耐药性结核分枝杆菌(TB)分离株中,耐多药结核病(MDR-TB)和广泛耐药结核病(XDR-TB)是令人日益关注的领域,一线抗生素对这些疾病已不再有效。因此,寻找针对结核病的新治疗靶点是当务之急。另一方面,针对特定目标进行药物筛选是药物研发的前提。此外,广泛耐药结核分枝杆菌(XDR-MTB)的完整蛋白质组数据的可用性使得对新药物靶点的计算机分析成为可能。在本研究中,我们旨在通过消减基因组学方法对 XDR-TB 的假设蛋白进行药物靶点的优先级排序。在消减基因组学中,我们逐步将 XDR-MTB 的完整蛋白质组减少到仅两种假设蛋白,并明确提出它们作为新的治疗靶点。两种候选靶蛋白之一的 3D 结构通过同源建模进行预测,随后通过各种分析工具进行验证。我们的研究表明,候选药物靶点的序列中鉴定的结构域和基序与 XDR-MTB 的存活有关。据我们所知,本研究首次尝试对 XDR-MTB 的完整蛋白质组数据进行计算消减基因组学分析,因此将有机会针对致命的 XDR-MTB 识别独特的治疗靶点。